



# Lamotrigine, a Very Polar Compound

## USP assay method



**Note:** Lamotrigine is a phenyltriazine anticonvulsant used to treat epilepsy and type I bipolar disorder. It is believed to act as a sodium channel blocker.

### Method Conditions

**Column:** Cogent Bidentate C18™, 4µm, 100Å

**Catalog No.:** 40018-15P

**Dimensions:** 4.6 x 150 mm

**Solvents:** A: 2.7 g/L KH<sub>2</sub>PO<sub>4</sub>: triethylamine 150:1, adjusted to pH 2.0 with H<sub>3</sub>PO<sub>4</sub>  
B: Acetonitrile

Gradient:	time (min.)	%B
	0	23.5
	4	23.5
	14	80
	15	23.5
	19	23.5

**Injection vol.:** 10µL

**Detection:** UV 270 nm

**Sample:** 25 mg strength tablet was ground and dissolved in 5 mL MeOH in a 100 mL volumetric flask. The flask was diluted to mark with 0.10 M HCl. It was sonicated and filtered with a 0.45µm nylon filter (MicroSolv Tech Corp.).

**Peak:** Lamotrigine

**t<sub>0</sub>:** 1.9 min

### Discussion

The USP assay method for lamotrigine uses a relatively low pH of 2.0. These conditions may promote hydrolysis of the bonded phase in conventional L1 columns, but the unique chemistry of the Cogent Bidentate C18 column is very rugged and shows no loss of retention for the API, as the five run overlay in the figure shows. The retention time %RSD for the five runs was 0.15%. In addition the peak shape was highly symmetrical.